Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by purseon May 15, 2015 11:15am
121 Views
Post# 23732808

Theratechnologies plaintiff gets court OK to drop suit

Theratechnologies plaintiff gets court OK to drop suit
2015-05-15 11:10 ET - News Release Shares issued 61,010,603 TH Close 2015-05-14 C$ 1.35 Ms. Jocelyn Lafond reports AUTHORIZATION TO DISCONTINUE CLASS ACTION PROCEEDINGS AGAINST THERATECHNOLOGIES GRANTED The Superior Court of Quebec has authorized 121851 Canada Inc. to discontinue all class action proceedings filed pursuant to the Securities Act (Quebec) and the Civil Code of Quebec against Theratechnologies Inc., a director, and a former president and chief executive officer. The authorization to discontinue the proceedings against the company, a director, and a former president and CEO results from the April 17, 2015, decision of the Supreme Court of Canada. The discontinuation of the proceedings by 121851 Canada in relation to this litigation will become effective on May 19, 2015.
Bullboard Posts